OBJECTIVES: It has been shown that increased metabolic activity of primary tumour has a negative effect on survival in non-small cell lung cancer (NSCLC) staged with positron emission tomography integrated computed tomography (PET/CT). We hypothesized that an increased metabolic activity of mediastinal lymph nodes would have worse survival even if it is false.
INTRODUCTION
The treatment of non-small cell lung cancer (NSCLC) depends on the stage of the disease [1] . Currently, positron emission tomography integrated computed tomography (PET/CT) is the best non-invasive staging modality in NSCLC [2] [3] [4] . The maximum standardized uptake value (SUV max ) created on an integrated PET/CT scan provides information on the metabolic activity of the primary tumour and mediastinal nodes [5] . Recently, it has been shown that increased metabolic activity of primary tumour has a negative effect on survival in NSCLC staged with PET/CT [6] .
The involvement of mediastinal lymph nodes is a critical prognostic factor in the planning of treatment modality. The superiority of PET/CT has been proved in the mediastinal staging of NSCLC [2] [3] [4] . The main drawback of PET/CT imaging is high false-positivity rate of mediastinal lymph nodes especially in regions where the prevalence of inflammatory lung diseases is high [4] .
In this study, with the guidance of prognostic effect of SUV max on primary tumour, we hypothesize that increased metabolic activity of mediastinal lymph nodes has worse survival despite being false.
MATERIALS AND METHODS

Patient selection
From September 2005 to March 2009, 328 consecutive patients with NSCLC histology were imaged with PET/CT within 90 days before mediastinoscopy and/or thoracotomy. A total of 42 patients were excluded: those who had neoadjuvant chemotherapy (n = 22), those with previous history of NSCLC (n = 9) or other malignancies within 5 years (n = 11). Patients' data were collected prospectively. Clinical stage IV patients were not included in this study. This study was approved by the Review Board of the hospital.
Positron emission tomography integrated computed tomography imaging
PET/CT images were obtained at 10 different centres, all of which used multi-detector CT-integrated PET scanners. Seventy-nine percent (225 patients) of imaging studies was performed at four different imaging centres that used the same detector (Siemens Biograph LSO HI-RES PET/CT; Siemens AG, Erlangen, Germany). Imaging technique of PET/CT was described previously [7] . Images acquired to detect mediastinal metastasis were visually evaluated. In the visual evaluation, fluorodeoxyglucose (FDG) uptake was considered to be positive in the evaluation of mediastinal lymph nodes if tracer activity was significantly higher than mediastinal background activity [8] . The SUV max for all primary tumours and positive lymph nodes was provided. A PET/CT scan was interpreted as positive if the SUV max of mediastinal lymph nodes exceeded 2.5. Lesions with their centre located within the medial one-third of the lung according to mediastinal pleura on transverse CT image were regarded as central, and others were regarded as peripheral.
Surgical staging
Premedication was not performed in any patient in the preoperative period. Induction of anaesthesia was performed with 1 µg/kg fentanyl (Fentanyl, Braun, Melsungen, Germany), 5-7 mg/kg thiopental (Pentothal Sodium, Abbott, Latina, Italy) and 0.1 mg/kg vecuronium (Blok-L, Mustafa Nevzat, Istanbul, Turkey). Intubation was done with double lumen tube in patients planned for lung resection. The correct position of endobronchial tube was confirmed with a fiberoptic bronchoscopy after intubation. Anaesthesia was maintained with 100% O 2 , 1-2% isoflurane (Forane, Abbott, Queensborough, Kent, England), 0.1 mg/kg vecuronium and 50 µg/h fentanyl.
Method for mediastinal lymph node staging has been previously described in detail [7] . In brief, mediastinal lymph node staging was completed in all patients by means of standard cervical mediastinoscopy, extended cervical mediastinoscopy and/ or thoracotomy. Patients with negative mediastinoscopy underwent resection and systematic lymph node sampling. Patients with positive mediastinoscopy were referred to the oncology clinic for neoadjuvant or definitive treatment.
All resected specimen and lymph nodes were examined by experienced pulmonary pathologist using standard techniques with immunohistochemistry performed as per the pathologist discretion. After localization and size measurement, the specimens were planed with a cryostat, serially sectioned (3-4 mm) and embedded, and then stained by standard haematoxylin and eosin. Pathological findings served as the gold standard at thoracotomy. The perioperative findings of all patients were discussed in our clinical meeting after the patient's discharge. Pathological results were revised according to the seventh tumor-nodemetastasis (TNM) staging system for this study [9] .
Data collection and patients' follow-up
Patients were followed-up for cancer recurrence and survival. Follow-up data were obtained every 3 months for the first 2 years and every 6 months afterwards in patients treated with surgical resection. In patients with advanced stage, follow-up were obtained mainly by the medical oncology department. Standard follow-up consisted of chest X-ray and clinical examination, a chest CT-scan with intravenous contrast was performed every year. PET/CT and other tests were also used if patients become suspected for disease recurrence. Survival information was obtained from patients' charts, hospital computer information systems, telephone calls and the Central Civil Registration System (MERNIS) of the Ministry of the Interior. Follow-up was completed between October 2010 and March 2011.
Definitions and statistical analysis
Overall survival was defined as the interval from the date of surgical intervention to the date of the last follow-up or death. Disease-free survival was defined as patients who were alive without recurrence and was measured only for those who underwent complete (R0) resection. Failure of treatment or recurrence of disease was counted as biopsy proven NSCLC or date of first imaging confirmation of disease recurrence or death without evidence of recurrence. Patients without recurrence or who were still alive at the end of this study were censored. Operative mortality was defined as a patient who died before hospital discharge or within 30 days of the operative procedure.
Univariate analyses were performed with the χ 2 test, Fisher's exact test and Mann-Whitney U-test wherever appropriate. The Kaplan-Meier survival analysis method was used for survival. Log-rank and Cox analyses were used for comparisons. Differences were considered significant when the P-value was less than 0.05. Statistical analysis and Kaplan-Meier curves were performed with the SPSS 15.0 for Windows (Statistical Package for Social Sciences, SPSS Inc. Chicago, IL, USA).
RESULTS
There were 286 patients (262 males and 24 females) with mean age of 58.5 ± 9.3 (range 33-81) years. Time interval between PET/CT and mediastinoscopy and/or thoracotomy was 16.3 ± 11.5 (range 2-90) days. The diagnosis of NSCLC was made in 220 (77%) patients preoperatively. Tumour and operative characteristics are listed in Table 1 . There were 22 (6.7%) operative deaths and none of the patients were lost to follow-up. The median follow-up in the remaining 264 patients was 26 months (range, 2-61 months). R0 resection has been performed in 209 patients of the 233 patients who underwent thoracotomy.
Patients were categorized into three groups according to primary tumour size. T1: x ≤ 3 cm, T2: 3 cm < x ≤ 7 cm and T3: x > 7 cm. Similarly, patients were categorized according to nodal spread as N0: no lymph node metastasis, N1: metastasis in intrapulmonary nodes and N2/3: metastasis in mediastinal nodes. Tumour size (T), nodal spread (N) and stage ( Fig. 1) were all strongly associated with survival from NSCLC (P < 0.001; Table 2 ).
There were 63 true-positive, 65 false-positive (FP), 152 truenegative (TN) and six false-negative findings in the evaluation of mediastinal lymph nodes with PET/CT. No mediastinal lymph node involvement was observed in 217 patients proven by histopathology in the study group. There were 109 FP lymph nodes on PET/CT in 65 patients with benign histopathology including anthracosis (n = 49), reactive hyperplasia (n = 11), granulomatous infection (n = 3) and fibrosis (n = 2).
Patients with no mediastinal lymph node involvement were classified as TN and FP. Univariate analysis of patient population, tumour characteristics and survival in patients with no mediastinal lymph node involvement are listed in Table 3 . Among all patients, median SUV max of primary tumour was 15.1 ± 6.8 in this study. SUV max of primary tumour was significantly higher in FP patients than in TN patients (P = 0.012). Type of operation, tumour size and pathological staging were all significantly associated with survival from NSCLC in patients with no mediastinal lymph node involvement. The mean survival for the group of TN patients was 3.4 years, whereas it was 2.5 years for the group of FP patients (P = 0.006; Table 3 and Fig. 2 ). Table 4 shows the multivariate Cox regression analysis for overall survival.
False-positivity of mediastinal lymph nodes was independently associated with worse survival in the multivariate analysis (hazard ratio = 0.63; P = 0.02). Tumour size and pathological staging were also independent prognostic factors for survival (hazard ratio = 1.43 and 1.67, respectively). There were 146 patients with pT1-4, pN0 treated with R0 surgical resection. The complete resection group did not include N1 lymph node positivity (n = 50), exploratory thoracotomy (n = 11), and microscopic (n = 8) or macroscopic (n = 2) invasion of the resection margin. Disease-free survival and overall survival 
DISCUSSION
Up to now, many clinical, pathological, routine laboratory markers, molecular, biological markers and gene signatures have been suggested as independent prognostic factors. The universally accepted TNM staging system is the most important prognostic factor from NSCLC [10] . We believe that, we have also confirmed the usefulness of the latest updated seventh TNM staging system with this study. Tumour size, nodal spread and TNM stage were all strongly associated with survival from NSCLC ( Fig. 1 and Table 2 ). Other important prognostic factors such as performance status, age and sex are all important but their usefulness is limited. However, patients belonging to the same stage can have different outcomes [11] . Therefore, further prognostic parameters are necessary in order to achieve better prediction of prognosis for each patient. Over the last decade, the use of PET imaging has increased in the staging of NSCLC worldwide. The principle of PET imaging is to detect malignant cells owing to their increased rate of glucose metabolism. On the basis of this principle, metabolic activity of primary tumour can correlate with tumour aggressiveness suggesting prognostic significance [5] . It has been shown in several recently published articles and the updated meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project that increased metabolic activity (SUV max ) of primary tumour has a negative effect on survival in NSCLC [6, 12, 13] . However, optimal threshold of SUV max and the type of threshold (i.e. median, best cut-off, arbitrary) used for SUV max are varying from one study to another. There was no prognostic significance of primary tumour FDG uptake in this study for the median SUV max of 15.1 (P = 0.991; data were not given in the results). Similarly, there are contrary data on the prognostic role of increased FDG uptake of primary tumour [14] .
In this study, the effect of FDG uptake in mediastinal lymph nodes on survival was investigated. We have shown that falsepositivity of mediastinal lymph nodes yielded worse survival in patients with no mediastinal lymph node involvement proven pathologically (P = 0.006; Fig. 2) . Similarly, disease-free survival and overall survival were better in TN patients than in FP patients in the complete resection group (Fig. 3a and b) . Notably, SUV max of primary tumour was significantly higher in the FP patients group (Table 3) . Although, prognostic significance of primary tumour FDG uptake could not be shown in this study, we believe that these results are in line with other studies [12, 13] . There may be correlated relationship between primary tumour FDG uptake and mediastinal lymph node FDG uptake which can impact survival together.
Lymph nodes play an essential role in the control of tumour progression. In response to the antigenity of tumour cells, regional lymph nodes may initiate and develop complex immune reactions. Acting as efficient barriers, the lymph nodes may be able to destroy invading tumour cells completely, or at least stop their dissemination temporarily [15] . In theory, metastasis into the mediastinal lymph nodes occurred in FP patients, but we could not detect metastasis histopathologically because tumour cells were already destroyed in the lymph nodes. It can be a result of increased cellular activity, glucose metabolism and FDG activity in the PET scan. In another theory, metastasis was in the early stage in these FP lymph nodes and we could not detect metastasis with routine histopathological examination. It is recommended to perform several sections of the nodes, 2 mm slices in the longitudinal plane and to examine each block separately. Immunohistochemistry using a cocktail of cytokeratins is a sensitive and specific method for detecting isolated tumour cells [16] . We recommend more detailed microscopic examination into the entire node and surrounding tissue with proper immunohistochemical staining in lymph nodes with positive uptake on PET scan.
A key goal of lung cancer research is to identify patients who are at high risk of developing post-resection recurrence, and those most likely to benefit from adjuvant treatment [17] . Recommendation for prospective randomized clinical trials of adjuvant chemotherapy in patients with early stage NSCLC and increased metabolic activity of primary tumour have been suggested to achieve better survival [18] . To our knowledge, there is no published prospective randomized trial to address this topic until now. There are several factors that affect measurement of SUV max in the PET imaging. Clinical decision on SUV max requires further study and a sophisticated approach [19] . Thus, it can be problematic to define universal optimal threshold of SUV max for randomization. We believe that this study may help in selecting patients based on mediastinal lymph node positivity in PET scan for additional therapy without any threshold of SUV max . However, it should be noted that optimal threshold of SUV max remains to be determined in patients with no mediastinal lymph node involvement in PET scan.
The first question that arises with these findings is: were patients with FP nodes staged accurately? We have shown that, overall survival curves according to latest TNM staging system were in accordance with the expected survival. Although, the sixth TNM staging map was used for nodal staging in this study [7] , survival analysis was made according to the seventh TNM staging. For nodal staging, the boundary between the right-and left-sided levels two and four lymph nodes has been reset to the left lateral wall of the trachea in the seventh TNM staging system [20] . As a result of this change, lymph nodes between the left lateral wall of the trachea and midline of the trachea were staged inaccurately from N2 to N3 or N3 to N2 according to primary tumour site. However, we believe that this discrepancy did not affect our results. Although mediastinal lymph node sampling was the method for nodal staging in this study, we performed complete dissection in stations with suspected metastasis during the surgical intervention. Moreover, a recent study from the American College of Surgery Oncology Group Z0030 trial has found that mediastinal lymph node dissection does not improve survival in patients with early stage NSCLC [21] .
In conclusion, we have shown that false-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable NSCLC patients staged with PET/CT. This result may help identify patients with potentially poor prognosis for additional therapy. Prospective randomized clinical trials are warranted. Finally, we think that SUV will continue to be popular among PET/CT researchers in the evaluation of lung cancer treatment in the future.
